Treatment with ustekinumab has been shown to be effective for ulcerative colitis (UC) in a real-world setting, according to a recent study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).
The standard 12-month duration of dual antiplatelet therapy (DAPT) remains the recommended regimen for patients receiving new-generation drug-eluting stents (DES) for the treatment of acute coronary syndrome (ACS) compared with a 3-month strategy despite the latter’s noninferiority to the former regimen, according to the results of the REDUCE* trial.
Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).
Among patients with ulcerative colitis (UC), vedolizumab serum concentrations in the fifth week after treatment initiation appear to have been higher in those who do vs do not show response in the sixth week, according to interim data from ENTERPRET study presented at the 2020 Crohn’s and Colitis Congress (CCC).
Evolocumab therapy demonstrates long-term efficacy, safety and tolerability in patients with homozygous (HoFH) and severe heterozygous familial hypercholesterolaemia (HeFH), reducing plasma low-density lipoprotein cholesterol (LDL-C) as well as the need for LDL apheresis, a study has shown.
Lim Jack Shen, assistant general manager of business development at Berjaya Corporation, talks about his experiences with developing MyTigas Alliance, a collaboration of independent community pharmacies for providing group healthcare services.
Use of virtual reality (VR) helps reduce pain during childbirth, and may present a novel nonpharmacologic approach to controlling labour pain, suggests a study presented at SMFM 2020 Annual Pregnancy Meeting in Grapevine, Texas, US.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng,
10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).